Literature DB >> 16651029

N-terminal proBNP levels in patients with Chagas disease: a marker of systolic and diastolic dysfunction of the left ventricle.

Marcia M Barbosa1, Maria do Carmo P Nunes, Antônio Luiz P Ribeiro, Marselha M Barral, Manoel Otávio C Rocha.   

Abstract

AIMS: NT-proBNP levels are known to be elevated in systolic and diastolic dysfunction. Doppler indices of diastolic dysfunction (DD) have been shown to have prognostic value in patients with Chagas' cardiomyopathy (CC). However, the additional value of NT-proBNP levels in further stratifying these patients according to DD has not been established. This study analyzed the correlation of N-terminal proBNP (NT-proBNP) levels with systolic and diastolic function in patients with CC. METHODS AND
RESULTS: NT-proBNP levels were measured in 59 patients with dilated cardiomyopathy due to Chagas disease without other systemic illness that were studied by Doppler echocardiography, including left atrial volume (LAV) calculation and tissue Doppler evaluation of LV longitudinal function. Univariate analysis showed a strong correlation of NT-proBNP values with LVEF (r=-0.733, p<0.001) and a weak correlation with most Doppler echocardiographic parameters of diastolic function. On a multivariate analysis, LVEF and LAV volume emerged as correlating with elevated levels of the NT-proBNP. Patients with restrictive filling pattern (n=10), when compared to other patterns of DD, (n=49), showed a lower LVEF (25.4+/-6.4% vs. 39.8+/-9.4, p<0.001), a larger LAV (50.1+/-17.2 vs. 37.7+/-15.6 ml/m(2), p=0.004) and higher NT-proBNP levels (median+/-IQR: 3488+/-3056 vs. 492+/-700 pg/dl, p<0.001). A marked elevated concentration of NT-proBNP (> or =800 pg/ml) had a sensitivity of 90.0%, specificity of 70.5%, positive predictive value of 40.9% and negative predictive value of 96.9% for detecting a restrictive filling pattern.
CONCLUSION: In patients with CC, NT-proBNP augmentation is a marker of LV dysfunction, with higher levels correlating with the more severe forms of both systolic and diastolic dysfunction.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16651029     DOI: 10.1016/j.euje.2006.03.011

Source DB:  PubMed          Journal:  Eur J Echocardiogr        ISSN: 1532-2114


  10 in total

1.  Inflammatory and cardiac biomarkers are differentially expressed in clinical stages of Chagas disease.

Authors:  S M Keating; X Deng; F Fernandes; E Cunha-Neto; A L Ribeiro; B Adesina; A I Beyer; P Contestable; B Custer; M P Busch; E C Sabino
Journal:  Int J Cardiol       Date:  2015-07-12       Impact factor: 4.164

Review 2.  Chronic Chagas' heart disease: a disease on its way to becoming a worldwide health problem: epidemiology, etiopathology, treatment, pathogenesis and laboratory medicine.

Authors:  Silvia Gilka Muñoz-Saravia; Annekathrin Haberland; Gerd Wallukat; Ingolf Schimke
Journal:  Heart Fail Rev       Date:  2012-01       Impact factor: 4.214

Review 3.  Diagnosis and management of Chagas disease and cardiomyopathy.

Authors:  Antonio L Ribeiro; Maria P Nunes; Mauro M Teixeira; Manoel O C Rocha
Journal:  Nat Rev Cardiol       Date:  2012-07-31       Impact factor: 32.419

Review 4.  Clinical and echocardiographic predictors of mortality in chagasic cardiomyopathy--systematic review.

Authors:  Clodoval de Barros Pereira Júnior; Brivaldo Markman Filho
Journal:  Arq Bras Cardiol       Date:  2014-06-06       Impact factor: 2.000

5.  Chagas cardiomyopathy: the potential of diastolic dysfunction and brain natriuretic peptide in the early identification of cardiac damage.

Authors:  Ana Garcia-Alvarez; Marta Sitges; María-Jesús Pinazo; Ander Regueiro-Cueva; Elizabeth Posada; Silvia Poyatos; José Tomás Ortiz-Pérez; Magda Heras; Manel Azqueta; Joaquim Gascon; Ginés Sanz
Journal:  PLoS Negl Trop Dis       Date:  2010-09-21

6.  Biomarkers in Trypanosoma cruzi-infected and uninfected individuals with varying severity of cardiomyopathy in Santa Cruz, Bolivia.

Authors:  Emi E Okamoto; Jacqueline E Sherbuk; Eva H Clark; Morgan A Marks; Omar Gandarilla; Gerson Galdos-Cardenas; Angel Vasquez-Villar; Jeong Choi; Thomas C Crawford; Rose Q Do; Rose Q; Antonio B Fernandez; Rony Colanzi; Jorge Luis Flores-Franco; Robert H Gilman; Caryn Bern
Journal:  PLoS Negl Trop Dis       Date:  2014-10-02

7.  Correlation of transforming growth factor-β1 and tumour necrosis factor levels with left ventricular function in Chagas disease.

Authors:  Eduardo Ov Curvo; Roberto R Ferreira; Fabiana S Madeira; Gabriel F Alves; Mayara C Chambela; Veronica G Mendes; Luiz Henrique C Sangenis; Mariana C Waghabi; Roberto M Saraiva
Journal:  Mem Inst Oswaldo Cruz       Date:  2018-02-19       Impact factor: 2.743

8.  Metabolic and immunological evaluation of patients with indeterminate and cardiac forms of Chagas disease.

Authors:  Ivonete Helena Rocha; Ana Luisa Ferreira Marques; Giselle Vanessa Moraes; Djalma Alexandre Alves da Silva; Marcos Vinicius da Silva; Virmondes Rodrigues; Daniel Ferreira da Cunha; Dalmo Correia
Journal:  Medicine (Baltimore)       Date:  2020-12-18       Impact factor: 1.817

9.  Cardiovascular Biomarkers and Diastolic Dysfunction in Patients With Chronic Chagas Cardiomyopathy.

Authors:  Luis E Echeverría; Sergio Alejandro Gómez-Ochoa; Lyda Z Rojas; Karen Andrea García-Rueda; Pedro López-Aldana; Taulant Muka; Carlos A Morillo
Journal:  Front Cardiovasc Med       Date:  2021-11-29

10.  Biomarkers and mortality in severe Chagas cardiomyopathy.

Authors:  Jacqueline E Sherbuk; Emi E Okamoto; Morgan A Marks; Enzo Fortuny; Eva H Clark; Gerson Galdos-Cardenas; Angel Vasquez-Villar; Antonio B Fernandez; Thomas C Crawford; Rose Q Do; Jorge Luis Flores-Franco; Rony Colanzi; Robert H Gilman; Caryn Bern
Journal:  Glob Heart       Date:  2015-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.